Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00008190 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | completed | Phase 2 | — | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00026351 | Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 2 | — | Pharmatech OncologyINDUSTRY | 1 | Feb 4, 2013 |
| clinicaltrials |
| NCT00230321 | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 21 | Peter L GreenbergOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00002704 | Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia | completed | Phase 2 | 156 | National Cancer Institute (NCI)NIH | 4 | Feb 1, 2013 | clinicaltrials |
| NCT01404936 | Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00003415 | Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 26 | University of ArizonaOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00030550 | Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome | completed | Phase 2 | — | Roswell Park Cancer InstituteOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00054171 | Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00452127 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 26 | Genentech, Inc.INDUSTRY | 0 | Jan 28, 2013 | clinicaltrials |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00002571 | SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma | completed | Phase 2 | 52 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00002657 | SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant | completed | Phase 2 | 20 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00003784 | S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 102 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00015834 | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00015990 | Thalidomide in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086944 | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00089388 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00401804 | Bortezomib-Dexamethasone-Doxorubicin-Study | completed | Phase 2 | 72 | Austrian Forum Against CancerOTHER | 2 | Jan 24, 2013 | clinicaltrials |
| NCT00005942 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006364 | Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00023920 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00054431 | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00084916 | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006053 | STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | completed | Phase 2 | — | NovartisINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00777738 | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia(WM2) | completed | Phase 2 | 34 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00003620 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00030394 | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00003632 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma | completed | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00016159 | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00047203 | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00093418 | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 296 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00321724 | AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT01086735 | Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation(ILD-TK01) | completed | Phase 1 / Phase 2 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00058305 | Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00335348 | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | completed | Phase 2 | 101 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00020800 | Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia | completed | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 4 | Jan 8, 2013 | clinicaltrials |
| NCT00066508 | Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy | completed | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2013 | clinicaltrials |
| NCT00081068 | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 5 | Jan 8, 2013 | clinicaltrials |
| NCT00090909 | Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2013source: clinicaltrials